TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.1% in the 4th quarter, Holdings Channel reports. The firm owned 383,113 shares of the biopharmaceutical company’s stock after acquiring an additional 504 shares during the quarter. Rhumbline Advisers’ holdings in TG Therapeutics were worth $11,532,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Brookstone Capital Management increased its stake in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 624 shares during the last quarter. Daymark Wealth Partners LLC increased its stake in shares of TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock worth $1,249,000 after acquiring an additional 689 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of TG Therapeutics by 1.9% in the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock worth $1,317,000 after acquiring an additional 837 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $30.88 on Monday. TG Therapeutics, Inc. has a 12 month low of $12.90 and a 12 month high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $31.07 and a 200-day simple moving average of $27.84. The stock has a market capitalization of $4.81 billion, a PE ratio of -308.77 and a beta of 2.26.

Analyst Upgrades and Downgrades

TGTX has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.